intrahepatic%20cholestasis
INTRAHEPATIC CHOLESTASIS
Cholestasis is bile formation &/or bile flow impairment that manifests as fatigue, pruritus and jaundice.
It can be classified into intrahepatic or extrahepatic cholestasis.
Extrahepatic cholestasis develops from mechanical blockage in the duct system or hepatocellular defects.
Intrahepatic cholestasis may be due to functional defects hepatocellularly or from obstructive lesions of the intrahepatic biliary tract distal from the bile canaliculi.

Introduction

  • Any condition that causes bile formation &/or bile flow impairment that may lead to:
    • Retention of conjugated bilirubin & its regurgitation into serum
    • Increased serum concentration of unconjugated bilirubin
    • Increased bile salts

Etiology

Extrahepatic cholestasis

  • Cholestasis that develops from mechanical blockage in the duct system or hepatocellular defects
  • It may be caused by stones, tumors, cysts, or strictures
  • This class will not be discussed here

Intrahepatic cholestasis (IHC)

  • Hepatocellular functional defects or presence of obstructive lesions in the intrahepatic biliary tract distal from bile canaliculi resulting to cholestasis
  • Chronic (lasts >6 months) cholestatic diseases are commonly intrahepatic

Signs and Symptoms

  • Fatigue
  • Pruritus
  • Jaundice
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Fiel Soliven, 18 Mar 2015
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
01 Feb 2016
Long-term ezetimibe improves lipid metabolism in dyslipidaemic patients with hepatobiliary disease, based on a study.
01 Feb 2016
Use of gadoxetate disodium for functional MRI can obtain useful data on hepatobiliary diseases, an article states.
Tristan Manalac, 14 Sep 2017
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.